Health ❯ Healthcare ❯ Pharmaceuticals

Drug Safety

Mifepristone Contaminated Drugs Counterfeit Medications Medication Recall Product Recall Product Recalls Contaminated Products Side Effects Quality Control Fentanyl Contamination Cough Syrups Contaminated Medications Drug Recalls Recalls Adverse Effects Counterfeit Drugs Fentanyl Contamination Issues Acetaminophen GLP-1 Drugs Regulatory Actions Contaminated Medicines Public Health Adulteration Adverse Drug Reactions Toxicology GLP-1 Receptor Agonists Toxic Substances Adverse Events Semaglutide Tirzepatide Health Risks Cough Syrup Contamination Black Box Warnings Medication Prohibition Contaminated Substances Puberty Blockers Regulatory Compliance Market Regulation Adverse Reactions FDA Regulations Child Health Clinical Trials Cough Syrup Contamination GLP-1 Medications Clinical Recommendations PFAS and Health Effects Opioid Medications Theft of Medicines Medication Alerts Duchenne Muscular Dystrophy Unlicensed Drugs Prenatal Medications Consumer Awareness Advertising Standards Chemical Abortion Market Withdrawals Metformina Advertising Compliance Medication Withdrawal REMS Program Good Manufacturing Practices Advisories Cough Syrup Tragedy RSV Treatments Regulatory Issues Regulatory Inspections Banned Substances Regulatory Review Antibiotics FDA Reviews Illegal Medications Fentanyl Investigation Regulatory Decisions Cannabis Patient Compensation Compensation Ivermectin Anticancer Medicines Contamination Risks Depo-Provera Medication Quality Control Meningioma Monitoring Systems Insulin Anticoagulants Liver Toxicity Nimesulide Dosing Errors Weight Loss Treatments Certification Standards Mifepristone Studies Data Integrity Anticancer Drugs Pancreatitis Levamisole GLP-1 Analog Medications Falsified Medications Codeine-based Medicines

Hawley Seeks Congressional Oversight of Mifepristone After FDA Offers No Timeline on Safety Review

The move follows a private FDA briefing that offered no timeline for its safety review.

Honey Energy Supplement Recalled After FDA Finds Undeclared ED Drug

DOJ Seeks Pause of Louisiana Abortion-Pill Lawsuit as FDA Reopens Mifepristone Review

Live Action Urges HHS and FDA to Suspend Mifepristone After Undercover Planned Parenthood Calls

Republicans Press Trump Administration to Halt Mail-Order Abortion Pills Crossing State Lines

FDA Seeks Removal of Suicide Warnings From Saxenda, Wegovy and Zepbound

AstraZeneca Withdraws Andexxa From U.S. Market After FDA Says Risks Outweigh Benefits

FDA Adds Brain Tumor Warning to Two Depo‑Provera Injections

FDA Clears First New Oral Gonorrhea Antibiotics in Over 30 Years

EU Regulator Backs Myqorzo for Obstructive Hypertrophic Cardiomyopathy

FDA Opens Safety Review of Infant RSV Antibody Drugs Beyfortus and Enflonsia

FDA Class III Recall Targets 11,136 Bottles of Ziac Over Trace Ezetimibe Contamination

Hawley Pressures FDA Chief as Anti‑Abortion Groups Demand Firing Over Reported Mifepristone Review Delay

Exicure’s Burixafor Delivers About 90% Stem-Cell Mobilization in Phase 2 as Shares Surge

FDA Class II Recall Targets Generic Vyvanse After Dissolution Failures

FDA Class II Recall Issued for 141,984 Bottles of Generic Atorvastatin Over Dissolution Failures

FDA Class II Recall Targets 580,000 Prazosin Bottles for Nitrosamine Overages

Teva, Amerisource Pull 580,000+ Prazosin Bottles as FDA Flags Nitrosamine Contamination

GOP Senators Press FDA Over Generic Abortion Pill Approval

FDA Class II Recall Targets 142,000 Bottles of Ascend’s Atorvastatin